PCAC 2026 Peptide Vote: What the FDA Panel Recommended

On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee met to evaluate whether several peptides, including BPC-157, should be added to the list of bulk drug substances that compounding pharmacies are permitted to use under Section 503A of the Federal Food, Drug, and Cosmetic Act. The committee's recommendations were advisory. The FDA is not bound by the vote but historically follows PCAC guidance in the majority of cases. This post covers what was voted on, how each peptide fared and what the results mean for access to compounded peptide products.

What the PCAC Voted On

The 503A Bulk Drug Substances List

Section 503A of the FD&C Act allows licensed compounding pharmacies to prepare customized medications for individual patients with valid prescriptions. For a substance to be compounded under 503A, it must either be a component of an FDA-approved drug or appear on the FDA's list of approved bulk drug substances for compounding. Peptides not on this list cannot legally be compounded by 503A pharmacies. The distinction matters because compounding pharmacies had been a primary access point for patients obtaining peptides like BPC-157 through prescriber supervision.

The FDA had previously placed several peptides on its Category 2 list, meaning the agency identified safety or efficacy concerns that warranted further review before allowing compounding use. The July 2026 PCAC meeting was convened to provide expert input on whether these substances should move to the approved bulks list or remain excluded. The meeting agenda and briefing documents were published in advance through the Federal Register notice 2026-07361.

Which Peptides Were Reviewed

The PCAC evaluated multiple peptide compounds across the two-day session. The peptides most relevant to this site's readership included BPC-157 (Body Protection Compound-157), KPV (a tripeptide derived from alpha-melanocyte-stimulating hormone), TB-500 (a synthetic fragment of thymosin beta-4) and MOTS-c (a mitochondrial-derived peptide). Each was assessed on two primary criteria: whether adequate safety data existed to support compounding use, and whether there was a clinical need that could not be met by FDA-approved alternatives. Committee members reviewed the FDA's briefing documents, heard presentations from agency scientists and invited public commentary before casting votes.

The Vote Results

BPC-157 Recommendation

The committee voted against recommending BPC-157 for inclusion on the 503A bulks list. The FDA's initial position going into the meeting was that BPC-157 lacked sufficient human safety and efficacy data to justify compounding. The committee agreed. Members cited the absence of completed human clinical trials, the reliance on a single research group for the majority of published data and the lack of characterized pharmaceutical formulations. A 2025 systematic review presented during the meeting identified 544 preclinical studies and just one qualifying clinical analysis across the entire BPC-157 literature, underscoring the gap between animal data volume and human evidence.

The vote was not unanimous. Several committee members acknowledged the preclinical signal and the volume of anecdotal patient reports. However, the majority concluded that anecdotal reports and animal data, regardless of volume, did not meet the evidentiary standard required for the bulks list. The FDA's position that it "lacks sufficient information to know whether [BPC-157] would cause harm when administered to humans" was cited repeatedly during discussion. For background on BPC-157's regulatory trajectory, see our BPC-157 therapy guide.

KPV, TB-500 and MOTS-c

KPV received a similar recommendation against inclusion. The committee noted limited published data and the absence of established pharmacokinetic parameters. TB-500, the synthetic thymosin beta-4 fragment, was also not recommended, with members flagging theoretical concerns about angiogenesis promotion in patients with undiagnosed malignancies. MOTS-c, a mitochondrial peptide studied for metabolic effects, faced the same evidentiary gap: promising rodent data with no completed human trials to validate the findings.

What the Vote Means

Advisory Votes Are Not Binding

PCAC recommendations are advisory. The FDA retains final authority over which substances appear on the 503A bulks list. In practice, the agency follows PCAC recommendations in the large majority of cases. Overruling the committee would require the FDA to articulate a justification for diverging from its own expert panel, which is bureaucratically and legally difficult. However, it has happened. Congressional pressure, public comment volume and new data submissions have all influenced final FDA decisions in past compounding rulemakings.

The advisory nature of the vote means the door is not permanently closed. If new human clinical data were published demonstrating safety and efficacy for BPC-157 or any other reviewed peptide, the FDA could revisit the question without reconvening the PCAC. The practical barrier is not regulatory procedure but the absence of that data. As detailed in our analysis of the clinical translation gap, no entity has announced plans for a Phase III BPC-157 trial.

Timeline for FDA Final Decision

The FDA typically issues a final rule within 12 to 18 months of a PCAC meeting, though timelines have varied. The Category 2 designation remains in effect during this period, meaning compounding pharmacies cannot legally use BPC-157 as a bulk substance under 503A while the rulemaking is pending. Some 503B outsourcing facilities may operate under different regulatory frameworks, but the trend is toward tighter enforcement across both categories.

For researchers and consumers, the practical effect is that prescription access to compounded BPC-157 through traditional pharmacy channels remains restricted. Research peptide vendors operating outside the pharmacy framework continue to sell BPC-157 under "research use only" labeling, which is a separate regulatory category. The PCAC vote does not directly affect research-use sales but does signal the FDA's current posture toward peptide compounds lacking human trial data. Our peptide safety guide covers the broader implications of using research-labeled products.

This article reports on a public FDA advisory committee proceeding. It does not constitute legal or medical advice. Individuals considering any peptide product should consult a healthcare professional and review the current regulatory status of the compound in their jurisdiction.

Sources

• FDA Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026. Meeting materials available at fda.gov/advisory-committees/pharmacy-compounding-advisory-committee
• Federal Register Notice 2026-07361. federalregister.gov/documents/2026/04/14/2026-07361
• Djakovic Z, et al. BPC 157: A Comprehensive Biopharmaceutical Evaluation. Pharmaceutics. 2025. PMID 42198317